Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24077354 | 0.86 | NLRP3 (0.56) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24077070 | 0.86 | NLRP3 (0.56) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24076297 | 0.86 | NLRP3 (0.56) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24077266 | 0.85 | NLRP3 (0.75) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24077274 | 0.84 | NLRP3 (0.66) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24077265 | 0.84 | NLRP3 (0.63) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL29348106 | 0.83 | NLRP3 (0.47) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24076874 | 0.82 | NLRP3 (0.63) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL24076296 | 0.81 | NLRP3 (0.51) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR | |
| SCHEMBL30168553 | 0.81 | NLRP3 (0.51) | NLRP3SMN1; SMN2AKR1B1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885SMN1; SMN2 4494/4885AKR1B1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.